Germany’s Stada Urged by Investor to Replace Five DirectorsBy
Active Ownership also proposes ending transfer limits on stock
Proposals submitted for annual shareholder meeting on June 9
Stada Arzneimittel AG, Germany’s largest maker of generic drugs, was urged by one of its top shareholders to replace five board members and remove a restriction on transfer of shares.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.